Diskusjon Triggere Porteføljer Aksjonærlister

Episurf Medical (EPIS-B)

Biotek
#806

Avstämningsdag för gratis teckningsoptioner av serie TO4B samt information om period för utnyttjande av teckningsoptioner av serie TO4B

Avstämningsdag för de teckningsoptioner av serie TO4B 2018/2023 som Episurf Medical AB (publ) (“Episurf”) delar ut till sina aktieägare för att minska utspädningen i den första tranchen i den finansieringslösning som Episurf genomförde den 2 maj 2018 är satt till den 30 maj 2018. Detta innebär att sista dag för handel med Episurfs aktie inklusive rätt att erhålla teckningsoption av serie TO4B är den 28 maj 2018. Första dag för handel exklusive rätt till teckningsoption av serie TO4B är den 29 maj 2018.

En (1) teckningsoption av serie TO4B tilldelas för varje heltal om tjugosju (27) aktier som innehas per avstämningsdagen den 30 maj 2018. Avrundning sker nedåt.
Innehav av en (1) teckningsoption av serie TO4B berättigar till teckning av en (1) nyemitterad aktie till en teckningskurs om 6,10 kronor under nedanstående perioder.
Teckning av nya aktier genom utnyttjande av teckningsoptioner av serie TO4B till ett sammanlagt värde om 500 000 kronor eller mer kan ske från och med dagen för registrering av beslutet att emittera teckningsoptionerna vid Bolagsverket till och med den dag som infaller fem (5) år efter dagen för registrering hos Bolagsverket. Emissionen av teckningsoptionerna av serie TO4B registrerades hos Bolagsverket onsdagen den 23 maj 2018.
Utnyttjande av teckningsoptioner som understiger sammanlagt 500 000 kronor kan ske vid fem tillfällen under den tvåveckorsperiod som föregår dagen för 6, 12, 18, 24, 30, 36, 42, 48, 54 respektive 60 månader efter den 23 maj 2018, dagen för registrering. Teckning av aktier med stöd av teckningsoptioner av serie TO4B kommer att vara möjligt under nedanstående perioder:
-     Torsdagen den 9 maj 2019 till och med torsdagen 23 maj 2019
-     Lördagen den 9 november 2019 till och med lördagen den 23 november 2019
-     Lördagen den 9 maj 2020 till och med lördagen 23 maj 2020
-     Måndagen den 9 november 2020 till och med måndagen den 23 november 2020
-     Söndagen den 9 maj 2021 till och med söndagen den 23 maj 2021
-     Tisdagen den 9 november 2021 till och med tisdagen den 23 november 2021
-     Måndagen den 9 maj 2022 till och med måndagen den 23 maj 2022
-     Onsdagen den 9 november 2022 till och med onsdagen den 23 november 2022
-     Tisdagen den 9 maj 2023 till och med tisdagen den 23 maj 2023
-     Torsdagen den 9 november 2023 till och med torsdagen den 23 november 2023

Teckningsoptionerna finns tillgängliga från 2018-06-01. Detta sker automatiskt via Euroclear som administrerar bolagets aktiebok.

För mer information, vänligen kontakta:

Pål Ryfors, vd, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

Om Episurf Medical

Episurf Medical arbetar för att erbjuda människor med smärtsamma ledskador ett aktivare och friskare liv genom att tillgängliggöra minimalt invasiva samt skräddarsydda behandlingsalternativ. Episurf Medicals individanpassade implantat Episealer® och kirurgiska instrument Epiguide® används för behandling av lokala broskskador i leder. Med Episurf Medicals μiFidelity®-system anpassas implantaten kostnadseffektivt till respektive persons unika skada för optimal passform och minimalt ingrepp. Episurf Medical har huvudkontor i Stockholm, Sverige. Aktien (EPIS B) är noterad på Nasdaq Stockholm. Mer information finns på bolagets hemsida: www.episurf.com.

Ekstern link: http://news.cision.com/se/episurf/r/avstamningsdag-for-gratis-teckningsoptioner-av-serie-to4b-samt-information-om-period-for-utnyttjande,c2529342
Ekstern link: http://mb.cision.com/Main/14691/2529342/846920.pdf

Nyheten er levert av Cision.

http://www.netfonds.no/quotes/release.php?id=20180523.Cision.20180523:BIT:4942:0

#807

Record day for free warrants of series TO4B as well as information about period for exercising warrants of series TO4B

Record day for the warrants of series TO4B 2018/2023 issued by Episurf Medical AB (publ) (“Episurf”) to its shareholders to protect them against dilution from the first tranche in the financing agreement executed by Episurf on May 2, 2018, is decided to 30th  May 2018. This means that 28th May 2018 is the last day of trading Episurf’s share, including the right to receive warrants in series TO4B. The first day of trading excluding the right to warrants in series TO4B is 29th  May 2018.

One (1) warrant of series TO4B is granted for 27 existing shares held by the shareholder on the record date 30th May 2018, rounded downwards.
Each warrant entitles the holder to subscribe for one (1) new Episurf share at a fixed strike price of SEK 6.10 during the periods below.
Subscription of new shares through the exercise of warrants of series TO4B for a total value of SEK 500,000 or more may take place from the registration date of the decision to issue the warrants at the Swedish Companies Registration Office until the last day of five (5) years after the registration date at the Swedish Companies Registration Office. The issue of warrants of series TO4B was registered at the Swedish Companies Registration Office on Wednesday, 23rd May  2018.

The exercise of warrants below an aggregated amount of SEK 500,000 may take place on ten occasions during the two-week period preceding the day of 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months after the date on which the warrants are registered at the Swedish Companies Registration Office, 23 May 2018. Subscription of shares based on warrants of series TO4B will subsequently be possible during the following periods:

  • Thursday, May 9, 2019 until Thursday, May 23, 2019
  • Saturday November 9, 2019 until Saturday, November 23, 2019
  • Saturday, May 9, 2020 until Saturday, May 23, 2020
  • Monday, November 9, 2020 until Monday, November 23, 2020
  • Sunday, May 9, 2021 until Sunday, May 23, 2021
  • Tuesday, November 9, 2021 until Tuesday, November 23, 2021
  • Monday, May 9, 2022 until Monday, May 23, 2022
  • Wednesday November 9, 2022 until Wednesday, November 23, 2022
  • Tuesday, May 9, 2023 until Tuesday, May 23, 2023
  • Thursday, November 9, 2023 until Thursday, November 23, 2023
    The warrants are available from 2018-06-01. This is executed automatically via Euroclear, which manages the company’s share register.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Ekstern link: http://news.cision.com/episurf/r/record-day-for-free-warrants-of-series-to4b-as-well-as-information-about-period-for-exercising-warra,c2529348
Ekstern link: http://mb.cision.com/Main/14691/2529348/846921.pdf

Nyheten er levert av Cision.

http://www.netfonds.no/quotes/release.php?id=20180523.Cision.20180523:BIT:4948:0

#808

Fantastisk engasjement fra Leif Ryd fra 49 minutter. :slight_smile:

1 Like
#809

Føler meg trygg på den duoen der

#810

Lite aktivitet her i det siste… Selv har jeg vært ute og bare fulgt kursen med et halvt øye siste månedene. Da jeg så kursen var nesten ned mot 5 blank denne uka hoppet jeg inn igjen med en lyttepost. Liker Episurf. Det er stilig og viktig teknologi som fremstår å ha enormt potensiale.

Antallet operasjoner har jo ikke eksplodert akkurat, men utviklingen av produktene ser jo unektelig bra ut, feks geografisk utbredelse, testresultater og godkjenningsløp. Stødig og trygg CEO ser det ut som.

Ser også at de har skaffet ytterligere finansiering, men warrants er ikke noe jeg kan særlig om. Noen her som kan si noe om denne finansieringsløsningen og evt fordeler og ulemper med den for selskap og aksjonærer?

5 Likes
#811

Episurf Medical has received initial feedback from the US FDA on the IDE application for the Episealer® knee implant

Episurf Medical (NASDAQ: EPIS B) today announces that the company has received initial feedback from the US Food and Drug Administration (FDA) on the Investigational Device Exemption (IDE) application for the Episealer® knee implant that was submitted in June.  The company filed the IDE application to get approval to initiate a clinical study in the US.

Episurf Medical has now received communication on the IDE application within 30 days according to FDA’s communicated timetable and now has some details to address prior to a finalised IDE study design will be set.

“We are now entering into the next phase for the IDE application. Episurf considers the FDA feedback as manageable and we are looking forward to continued work with our advisors to get the IDE study up and running according to our initial schedule” comments Pål Ryfors, CEO, Episurf Medical.  

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 30 July 2018.

Ekstern link: http://news.cision.com/episurf/r/episurf-medical-has-received-initial-feedback-from-the-us-fda-on-the-ide-application-for-the-episeal,c2583187
Ekstern link: http://mb.cision.com/Main/14691/2583187/884536.pdf

Nyheten er levert av Cision.

http://www.netfonds.no/quotes/release.php?id=20180730.Cision.20180729:BIT:9287:0

#812

New US patent approval for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent, entitled “System of designing a guide tool and/or surgical kit tools and/or an implant comprising a positioning mark”, covers specific features for accurate placement of Episurf Medical’s individualised joint implants.

“The Episealer® technology contains a number of delicate features, and the implant positioning solution for correct placement is one of these. We are happy to get that protected in the US. Episealer® is not just an implant but also comprises a userfriendly, proprietary set of surgical instruments and a damage marking report for surgical pre-planning”, comments Pål Ryfors, CEO, Episurf Medical.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 3 August 2018.

Ekstern link: http://news.cision.com/episurf/r/new-us-patent-approval-for-episurf-medical,c2585663
Ekstern link: http://mb.cision.com/Main/14691/2585663/886397.pdf

Nyheten er levert av Cision.

http://www.netfonds.no/quotes/release.php?id=20180803.Cision.20180802:BIT:1763:0

#813

New Australian patent approval for Episurf Medical

The Australian patent office IP Australia has announced that Episurf Medical (NASDAQ: EPIS B) has obtained another granted patent in Australia.

The patent, entitled “Surgical kit for cartilage repair comprising implant and a set of tools”, has a focus on the company’s individualised Episealer® Femoral Twin implant and its design.

“The Episealer® twin technology is an appreciated solution for the commonly occurring elongated cartilage lesions, and we thus welcome this first approval of this patent family”, comments Pål Ryfors, CEO, Episurf Medical.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.35 CEST on 3 August 2018.

Ekstern link: http://news.cision.com/episurf/r/new-australian-patent-approval-for-episurf-medical,c2585668
Ekstern link: http://mb.cision.com/Main/14691/2585668/886399.pdf

Nyheten er levert av Cision.

http://www.netfonds.no/quotes/release.php?id=20180803.Cision.20180802:BIT:1768:0

#814

Gikk tydeligvis inn litt tidlig, men økte på 4,2. :blush:

Fin stigning i dag, selv om jeg ikke tror slike patentmeldinger alene skaper varig kursendring. Samtidig virker aksjen ganske glemt nå så mye kan skje fort om det snur. Vanskelig å si hva som evt blir triggeren.

1 Like
#815

Selskapet er mer lovende enn noen gang, aksjen er bittelitt tvilsom akkurat nå.

#816

30% opp så langt i dag! Som sagt, ikke lett å si hva som trigger de store bevegelsene :stuck_out_tongue_winking_eye:

Jeg solgte på 18% opp i dag…fordi 18%, men det viste seg å være tidlig gitt…

2 Likes
#817

I alle dager.

Kan umulig være patentinnvilging som gjør det.

Lekkasjer?

#818

Ja, ikke sant? Patentene er fint det, men hallo!? Tror fremdeles den siger tilbake de nærmeste dagene hvis ikke, som du er inne på, noe mer kommer.

Edit: Den snudde ned på ma 150/200.

#819

Touchet oppimot 200 ja:

200/400 tegnet inn her:

image

#820

Hvis man ser på tilsvarende grønne volumspikes siden 2016, så har dessverre alle disse oppgangene vært temmelig kortlivede… For min del håper jeg jo mønsteret gjentar seg, men en gang kan det jo snu :slight_smile:

#821

Caset er på noen måter likt Photocure, teknologien fremstår strålende, men det tar tid å bygge business.

Og så er det USA som er den hellige gral.

Edit:

Du och jag Pål, du och jag. :wink:

image

Pål er ellers en sympatisk no bullshit kar med rikelig med skin in the game:

http://episurf.com/episurf-medicals-ceo-paal-ryfors-acquires-shares-corresponding-to-3-2-of-capital-and-6-8-of-votes-from-main-shareholder-serendipity-ixora/

http://episurf.com/episurf-medicals-board-names-paal-ryfors-new-ceo-and-appoints-new-cfo/

6 Likes
#822

Episurf toget endelig kommet i gang?

Tuut :train:

#823

Noen spesiell grunn til at den har gått så mye ? Har bare en lyttepost her men har som vanlig glemt å lytte :wink:

1 Like
#824

Kan ikke se noe spesielt, noen som handler med Danske bank har kjøpt en del i dag

1 Like
#825

Stengte over sma 200 :rocket:

1 Like